Robert S. DiPaola, MD

Dr. DiPaola Honored for Contributions to Oncology Field
 

Dr. DiPaola Authors Editorial in the Journal of Clincal Oncology

Journal of Clinical OncologyCabozantinib in Prostate Cancer:
The Beginning of
a Precision Paradigm?


 

View Dr. DiPaola's Research Profile
 

Dr. DiPaola Discusses Precision Medicine in UMDNJ Magazine, Winter 2013 Edition
 

Dr. DiPaola Receives Top Doc Honors in 2012 U.S. News & World Report

 

Dr. DiPaola Video
Video: Dr. DiPaola is interviewed by
NJ 101.5's David Matthau

Robert S. DiPaola, MD


Director
Rutgers Cancer Institute of New Jersey

 


 




Bio

As Cancer Center Director, Dr. DiPaola is responsible for research activities and administrative oversight of a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, and led the successful renewal of NCI designation in 2011. Dr. DiPaola has held multiple local and national positions including the founding Director and Program leader of the Prostate Cancer Center at the Cancer Institute of New Jersey (1996-2008); National Chairman of the Genitourinary Committee of the Eastern Oncology Cooperative Group (2004-2011); Chief of Medical Oncology at Robert Wood Johnson Medical School (2006-Current); and was appointed as Director of the Cancer Institute of New Jersey in 2008, after a national search. Dr. DiPaola has considerable experience in translational research focused on the study of prostate cancer and drug resistance locally and nationally. He was one of the earliest investigators to target the degradation of bcl-2 in both the laboratory and clinic as a means to restore drug sensitivity. His accomplishments in the area of translational research are underscored by grants from the NIH, Department of Defense, and private foundations, as well as his publications in prominent journals including the New England Journal of Medicine, JAMA, Cell, Clinical Cancer Research, and the Journal of Clinical Oncology.

Dr. DiPaola has maintained continuous federal peer-reviewed funding to support a laboratory focused on Drug Resistance in Cancer Therapy focused on preclinical studies that support translational clinical trials. He is PI of a Cancer Center Support Grant, a CINJ phase I/II U01 grant supporting translational clinical trials, and Department of Defense Prostate Consortium Grant focused on the development of translational studies in prostate cancer. As Chairman of the Genito-Urinary Committee of the Eastern Cooperative Oncology Group (ECOG) for a term from 2004 until 2011, he led the committee to develop National phase II and III studies, and through two successful NCI reviews. He continues as a full member of multiple NCI steering committees, including the investigational drug steering committee and the Genitourinary steering committee, and is chairman of an NCI apoptosis and autophagy task force. He was appointed as a full member of the National Cancer Institute's subcommittee A (parent committee) for Cancer Center reviews and was chairman for this year's American Society of Clinical Oncology's GU program committee.
 

Board Certifications

  • Diplomate, Internal Medicine,1991 - 2021
  • Diplomate, Medical Oncology,1995 - 2015
  • Hematology,1994 - 2004
     

Education / Training

  • Fellowship, Hematology-Oncology, University of Pennsylvania Hospital, Philadelphia, PA
  • Residency, Internal Medicine, Duke University Medical Center, Durham, NC
  • Internship, Internal Medicine, Duke University Medical Center, Durham, NC
  • MD, Medicine, University of Utah School of Medicine, Salt Lake City, UT
  • BS, Science, University of Utah, Salt Lake City, UT

 

Professional Organizations

  • American Association for Cancer Research (AACR)
  • American Society of Clinical Oncology (ASCO)
  • Eastern Cooperative Oncology Group (ECOG)
  • Oncology Society of New Jersey
  • Prostate Cancer Foundation (PCF)
     

Select Awards and Honors

  • Voted in “Best Doctors in America,” 1998, 2005, 2007, 2011, 2012, 2013
  • Awarded Research Mentor of the Year, Department of Medicine, UMDNJ-RWJMS, 2005
  • Awarded the ECOG 2003 Investigator Award, 2003
  • Voted in “CaRelations Physician of the Year,” 2000
  • Elected Junior Faculty Representative, RWJMS, 1996
  • American Cancer Society Clinical Oncology Fellowship Award, 1993 - 1994 

Select Committees / Leadership

  • Full Member, NCI IRG Subcommittee A – Cancer Centers Branch (Parent Committee), 2012 - 2016 
  • Member, NCI National Clinical Trials Network (NCTN) Working Group of the CTAC Clinical Trials Strategic Planning Subcommittee, 2012 - Current
  • Chairman, AACI/CCAF Annual Meeting Program Committee, 2014
  • Chairman, ASCO Genitourinary Cancers Symposium Program Committee, 2014
  • Member, Rutgers University Search Committee for Chancellor of Biomedical and Health Sciences, 2012
  • Member, AACR Clinical Research and Experimental Therapeutics Awards Selection Committee, 2012
  • Member, AACR Annual Meeting Program Committee, Clinical Research Subcommittee: Translational Research and Molecular Biology, 2012 - Current
  • Member, Fox Chase Cancer Center, External Advisory Board, 2012 - Current
  • Member, Winship Cancer Institute at Emory University, External Advisory Board, 2012 - Current
  • Chairman, ASCO Genitourinary Cancers Symposium Program Committee, 2014
  • Member, AACR Science Policy and Legislative Affairs Committee and AACR Clinical Guidelines Task Force Leader, 2010 - Current
  • Member, University of Hawaii Cancer Center, External Advisory Board, 2010 - Current
  • Voting Member, NIH/NCI Investigational Drug Steering Committee, 2008 - Current
  • Chairman, NCI CTEP Investigational Drug Steering Committee DNA Damage-Repair and Tumor Cell Death Task Force, 2008 - Current
  • Member, ASCO GU Cancers Symposium Program Committee, 2008 - 2011
  • Chairman, AACR Centennial Grant Review Section Committee, 2008
  • Member, AACR/EORTC Symposium Program Committee, 2008
  • Current Voting Member, NCI Genitourinary Steering Committee, 2007 - Current
  • Full Member, NIH/NCI Clinical Oncology Grant Review Study Section, 2006 - 2010
  • National Chairman, Genitourinary Committee of the Eastern Cooperative Oncology Group (ECOG), 2004 - 2011
  • Member/Leader, American Society of Clinical Oncology (ASCO) Scientific Program Committee, 2004 - 2006
  • Grant Study Section Member, Department of Defense (DOD), Breast Cancer Committee, 2003 - 2004
  • Grant Study Section Member, Department of Defense (DOD): Clinical and Experimental Therapeutics-2 in Prostate Cancer, 2002 - 2005
  • Roundtable Member, Environmental Health Sciences at the Institute of Medicine in the National Academy of Sciences, 2001
     

United States Patents

Patent No.: US 6,498,195 B2
Patent Date: December 24, 2002
Title: Use of 1-Propanone-1-(2,4- Dihydroxyphenyl)-3-Hydroxy-3-(4' Hydroxyphenyl) as an Anticarcinogenic Agent.

Patent No.: US 6, 627, 623
Patent Date:  September 30, 2003
Title:  Inducing cell apoptosis and treating cancer using 1-O-acetylbritannilactone or 1,6-O,O-diacetylbritannilactone.
 

Laboratory Research Experience / Efforts

Translational research and drug resistance in cancer therapy, 1997 - Current 
Rutgers, Cancer Institute of New Jersey
Funding has been continuously maintained as Principal Investigator to support a laboratory focused on preclinical studies that support translational clinical trials in multiple malignancies with a specific focus in prostate cancer.       

Treatment of human malignancy with antisense oligodeoxynucleotides, 1992 - 1994
In collaboration with Alan Gewirtz MD, University of Pennsylvania
The focus of this research was on laboratory studies defining the importance of kit Receptor in solid tumors, and to develop therapeutics for translational clinical trials during Hematology/Oncology Fellowship at the University of Pennsylvania. (1) DiPaola RS, Kuczynski WI, Onodera K, Ratajczak M, Hijiya N, Moore J and Gerwirtz AM: Evidence for a functional kit receptor in melanoma, breast and lung carcinoma cells.  Cancer Gene Therapy, 4:176-182, 1997; (2) Luger SM, Ratajaczak WI, Kuczynski WI, DiPaola RS, Ngo W, Clevenger CV and Gewirtz AM: A Functional analysis of protooncogene Vav’s role adult human hematopoiesis. Blood, 87(4): 1326-1334, 1996; (3) Salhany KE, Feldman M, Kahn MJ, Peritt D, Schrentzenmair R, Darren M, Wilson BA, DiPaola RS, Glick AD, Kant JA, Nowell PC and Kamoun M:  Hepatosplenic gamma/delta T-Cell Lymphoma: ultrastructural, immunophenotypic, and functional evidence for cyotoxic T Lymphocyte differentiation. Human Pathology 28:675-685, 1997; and (4) DiPaola RS, Orel S and Fowble B: Ipsilateral breast tumor recurrence after conservative surgery and radiation. Oncology, 8:59-68, 1994.

Iron recycling in macrophage cell systems, 1987 - 1988
with J.H. Ward, MD, University of Utah 
 

Current Federal Grants

Grant Number: P30 CA072720-16
Source: NIH / NCI
Project Title/Goal: Cancer Center Support Grant (CCSG).  The Cancer Center Support Grant supports programs and core resources for the NCI-designated Comprehensive Cancer Center.
Role: Principal Investigator

Grant Number: U01 CA132194-05
Source: NIH / NCI
Project Title/Goal: Early Clinical Trials of New Anti-cancer Agents with Phase I Emphasis.  The major goal of this project is to develop and perform early clinical trials with new anti-cancer agents sponsored by the NCI Cancer Therapy Evaluation Program.
Role: Principal Investigator

Grant Number: U01 CA107868
Source: NIH / NCI
Project Title/Goal: Participation in the Eastern Cooperative Oncology Group. The major goals of this grant are to continue our strong ECOG committee participation, design and participate in ECOG multi-modality studies, engage our peer-reviewed institutional laboratories, foster continued accrual from our broad network of affiliated institutions and other relevant purposes to enhance the interaction of basic science laboratories and the group’s clinical trials program.
Role: Co-Investigator

Grant Number: R01 CA116399-01-05
Source: NIH / NCI
Project Title/Goal: Evaluation of Palliative Prostate Cancer Among Elderly Men. The major goal of this study is to compare overall and prostate cancer specific survival among elderly patients receiving primary androgen deprivation therapy and conservative management for non-metastatic prostate cancer diagnosis.
Role: Co-Investigator

Grant Number: W81XWH-09-1-0145
Source: Department of Defense, Prostate Cancer Clinical Trials Consortium
Project Title/Goal: Clinical Research Site Therapeutic Targeting of Molecular Pathways in Prostate Cancer. The major goal of this project includes the development of investigator-initiated clinical trials that are conducted across multiple university cancer centers within the Consortium.
Role: Principal Investigator

Grant Number: W81XWH-09-1-0394
Source: Department of Defense
Project Title/Goal: Modulating Drug Resistance in Prostate Cancer. The major goal of this project is to continue scientific projects focused on apoptosis and metabolic targeting in prostate cancer.
Role: Principal Investigator

Grant Number: U01 CA132194-05
Source: NIH/NCI
Project Title/Goal: Early Clinical Trials of New Anti-cancer Agents with Phase I Emphasis.  The major goal of this project is to develop and perform early clinical trials with new anti-cancer agents sponsored by the NCI Cancer Therapy Evaluation Program.
Role: Principal Investigator
 
Grant Number: R01 CA127729-01-05
Source: NIH / NCI
Project Title/Goal: Influence of Selenium on Biomarkers in Prostate Cancer Risk. The major goal of this project is the assessment of selenium in a clinical trial in men.  This is a collaborative effort with Penn State.
Role: Co-Investigator

Grant Number: R01 CA145722-01
Source: NIH / NCI
Project Title/Goal: Evaluate Long-term Prognosis of Localized Prostate Cancer Following Initial Radiation Therapy. The major goal of this study is to provide long-term outcome benchmarks critical for treatment decisions.  When completed this will be the longest and largest analysis to-date of longitudinal data on survival, use of subsequent cancer therapies, and prevalence of long-term serious cancer related complications among elderly patients with screen-detected localized prostate cancer treated with radiation therapy vs. conservative management.
Role: Co-Investigator
 

Select Publications

Raez LE, Papdopoulos K, Ricart AD, Chiorean EG, DiPaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J and Lampidis TJ.  A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol, 71(2):523-30, 2013. PMID:  23228990

Lin H, Gounder MK, Bertino JR, Kong AN, DiPaola RS and Stein MN.  A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies. J Pharm Biomed Anal, 66:371-5, 2012. PMID: 22483642  PMCID: 3358459

Hudson SV, Miller SM, Hemler J, Ferrante JM, Lyle J, Oeffinger KC and DiPaola RS. Adult cancer survivors discuss follow-up in primary care: ‘not what i want, but maybe what I need’. Ann Fam Med, 10(5):418-27, 2012. PMID: 22966105   PMCID: 3438209

Bray K, Mathew R, Lau A, Kamphorst JJ, Fan J, Chen J, Chen HY, Ghavami A, Stein M, Dipaola RS, Zhang D, Rabinowitz JD and White E. Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. PLoS One, 7(7):e41831, 2012. PMID: 22848625   PMCID: 3406086

Goodin S and DiPaola RS.  Cabozantinib in Prostate Cancer:  the beginning of a precision paradigm?  J Clin Oncol, 31(4):401-3, 2013. PMID: 23248244

Lu-Yao GL, Albertsen PC, Li H, Moore DF, Shih W, Lin Y, Dipaola RS and Yao SL. Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer? Eur Urol, 62(6):966-72, 2012.  PMID: 22608160 PMCID: 3472155

Lin H, Gounder MK, Bertino JR, Kong AN, DiPaola RS and Stein MN.  A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies. J Pharm Biomed Anal, 66:371-5, 2012.  PMID: 22483642 PMCID: 3358459

Stein MN, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D, Eddy S, Shih W, and DiPaola RS. Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.  Med Sci Monit, 18(4):CR260-4, 2012.   PMID: 22460098

Stein MN, Goodin S and DiPaola RS.  Abiraterone in prostate cancer: a new angle to an old problem.  Clin Cancer Res, 18(7):1848-54, 2012.  PMID: 22451619

Liu G, Chen YH, DiPaola RS, Carducci M and Wilding G. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.  Clin Genitourin Cancer, 10(2):99-105, 2012. PMID: 22386239   PMCID: 3535436

Saleem A, Dvorzhinski D, Santanam U, Mathew R, Bray K, Stein M, White E and Dipaola RS. Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate, 72(12):1374-81, 2012.  PMID: 22241682

Alva A, Slovin S, Daignault S, Carducci M, DiPaola RS, Pienta K, Agus D, Cooney K, Chen A, Smith DC and Hussain M.  Phase II study of cilengitide (EMD 121974, NSA 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs, 30(2):749-57, 2012. PMID: 21049281   PMCID: 3175265

Holen K, DiPaola RS, Liu G, Tan AR, Wilding G, Hsu K, Agrawal N, Chen C, Xue L, Rosenberg E and Stein M. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.  Invest New Drugs, 30(3):1088-95, 2012.  PMID: 21424701  PMCID: 3394096

Gounder MK, Lin H, Stein M, Goodin S, Bertino JR, Kong AN and DiPaola RS. A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasmaBiomed Chromatogr, 26(5):650-4, 2012.   PMID: 21932382

Liu G, Chen YH, Kolesar J, Huang W, DiPaola RS, Pins M, Carducci M, Stein M, Bubley GJ and Wilding G.  Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol, Jul 22, 2011.  PMID: 21784672   PMCID: 3223557

Delnevo CD, Steinberg MB, Hudson SV, Ulpe R and DiPaola RS. Epidemiology of cigarette and smokeless tobacco use among south asian immigrants in the northeastern United States.  J Oncol, 252675, 2011.  PMID: 21772842   PMCID: 3136136

Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen G, Lemons JM, Karantza V, Coller HA, DiPaola RS, Gelinas C, Rabinowitz JD and White E. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis.  Genes Dev, 25(5):460-470, 2011.  PMID: 21317241   PMCID: 3049287

Bradley DA, Daignault S, Ryan CJ, DiPaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET and Hussain M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.  Invest New Drugs, 29(6):1432-40, 2011.  PMID: 20336348 PMCID: 2917503

Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT and White E.  Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res, 17(4):654-66, 2011. PMID: 21325294 PMCID: 3075808

Parekh N, Lin Y, DiPaola RS, Marcella S and Lu-Yao G.  Obesity and prostate cancer detection: insights from three national surveys.  Am J Med, 123(9):829-35, 2010.  PMID: 20800152

Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, DiPaola RS and Lu-Yao GL. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med, 170(14):1256-61, 2010.  PMID: 20660846

Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, Eddy S, Goodin S, White E and DiPaola RS. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate, 70(13):1388-94, 2010.  PMID: 20687211

DiPaola RS, Chen YH, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth B, White E and Wilding G. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med, 8:20, 2010. PMID: 20178647  PMCID: 2837641
 

Additional Publications 

  • Publications 2006 - 2009

    Bray K, Chen HY, Karp CM, May M, Ganesan S, Karantza-Wadsworth V, DiPaola RS and White E.  Bcl-2 modulation to activate apoptosis in prostate cancer. Mol Cancer Res, 7(9):1487-96, 2009.  PMID: 19737977   PMCID: 2855683

    Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O’Leary M, Walker-Corkery E and Yao SL. Outcomes of localized prostate cancer following conservative management. JAMA, 302(11):1202-9, 2009. PMID: 19755699 PMCID: 2822438

    Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, DiPaola RS and Lu-Yao GL. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst, 101(18):1280-3, 2009.  PMID: 19713548   PMCID: 2744729

    White E and DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res, 15(17):5308-16, 2009.  PMID: 19706824   PMCID: 2737083

    Dreicer R, Li H, Stein M, DiPaola RS, Eleff M, Roth BJ and Wilding G.  Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.  Cancer, 115(18):4090-5, 2009.  PMID: 19536901   PMCID: 2774800

    Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, DiPaola RS, Karantza-Wadsworth V and White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell, 137(6):1062-75, 2009.  PMID: 19524509 PMCID: 2802318 

    Jiang Y, DiPaola RS and Hu L. Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA).  Bioorg Med Chem Lett, 19(9):2587-90, 2009.  PMID: 19345094 

    Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, DiPaola RS and Crawford ED.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol, 20;27(15):2450-6, 2009.  PMID: 19380444   PMCID: 2684851

    Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS and Johri AR.  Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol, 20(3):492-7, 2009.  PMID: 19087985 

    DiPaola RS, Dvorzhinski D, Thalasila A, Garikapaty V, Doram D, May M, Bray K, Mathew R, Beaudoin B, Karp C, Stein M, Foran DJ and White E. Therapeutic starvation and autophagy in prostate cancer:  a  new paradigm for targeting metabolism in cancer therapy.  Prostate, 68(16):1743-52, 2008.  PMID: 18767033   PMCID: 2855052

    Lu-Yao GL, Albertson PC, Moore DF, Shih W, Lin Y, DiPaola RS and Yao SL. Survival following primary androgen deprivation therapy among men with localized prostate cancer.  JAMA, 300(2):173-81, 2008.  PMID: 18612114   PMICD: 2645653

    DiPaola RS and Gallo MA. Hearsay medicine is not evidence-based medicine. Clin Cancer Res, 14(2):337-8, 2008.  PMID: 18223204

    DiPaola RS and Lattime EC. Bacillus calmette-guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy. J Urol, 178(5):1840-1, 2007. PMID: 1786874 

    Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB and Kabbinavar FF. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.  BJU Int, 100(4):765-9, 2007.  PMID: 17822457

    Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E and Eisenberger MA.  Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.  J Urol,177(5):1777-81, 2007.  PMID: 17437819 

    Bradley DA, Hussain M, DiPaola RS and Kantoff P.  Bone directed therapies for prostate cancer.  J Urol, 178 (3 Pt 2):S42-8, 2007.  PMID: 17644119

    Kantoff PW, Beer TM, D'Amico AV, DiPaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM and Carroll PR.  Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference.  J Urol, 178(3 Pt 2):S5-8, 2007.  PMID: 17644118

    Mathew P and DiPaola RS. Taxane refractory prostate cancer. J Urol, 178(3 Pt 2):S36-41, 2007.  PMID: 17644120 

    Goodin S, Shen F, Shih WJ, Dave N, Kane MP, Medina P, Lambert GH, Aisner J, Gallo M and DiPaola RS. Clinical and biological activity of soy protein supplementation in health male volunteers. Cancer Epidemiol Biomarkers Prev, 16(4):829-33, 2007. PMID: 17416779

    Jin S, DiPaola RS, Mathew R and White E.  Metabolic catastrophe as a means to cancer cell death. J Cell Sci, 120(Pt 3):379-83, 2007.  PMID: 17251378  PMCID: 2857576

    Lu-Yao G, Moore DF, Oleynick JU, DiPaola RS and Yao SL. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.  J Urol, 177(2):535-9, 2007.  PMID: 17222628

    Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, DiPaola RS and Abate-Shen C. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1; Pten mutant mice.  Clin Cancer Res, 12(19):5895-901, 2006.  PMID: 17020998

    Lu-Yao G, Moore DF, Oleynick J, DiPaola RS and Yao SL.  Use of hormonal therapy in men with metastatic prostate cancer.  J Urol, 176(2):526-31, 2006.  PMID: 16813882

    Beekman KW, Colevas AD, Cooney K, DiPaola RS, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D and Hussain M. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 4(4):299-302, 2006.  PMID: 16729916

    Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G and DiPaola RS. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.  Clin Cancer Res, 12(7 Pt 1):1966-9, 2006. PMID: 16609005

    DiPaola RS and Morton RA. Proven and unproven therapy for benign prostatic hyperplasia.  New Engl J Med, 354(6):632-4, 2006.  PMID: 16467551

    DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K and Schuetz T. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med, 3;4:1, 2006.  PMID: 16390546  PMCID: 1360095

    • Publications 2002 - 2005

      Doyle-Lindrud S and DiPaola RS.  Future directions of therapy in prostate cancer: A focus on bone health.  Cancer Therapy, 3:401-406, 2005.

      Arlen PM, Kaufman HL and DiPaola RS.  Pox viral vaccine approaches.  Semin Oncol, 32 (6):549-55, 2005.  PMID: 16338420 

      DiPaola RS and Thompson IM. National cooperative group trials. Urology 65(5 Suppl):23-9, 2005.  PMID: 15885277

      Goodin S, Rao KV, Kane M, Dave N, Capanna T, Doyle-Lindrud S, Engle E, Jin L, Todd M and DiPaola RS.  A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.  Cancer Chemother Pharmacol, 56(2):199-204, 2005.  PMID: 15838657

      Goodin S, Medina P, Capanna T, Shih WH, Abraham S, Winnie J, Doyle-Lindrud S, Todd M and DiPaola RS.  Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol, 23(15):3352-7, 2005.  PMID: 15738531 

      Morris MJ, Cordon-Cardo C, Kelly WK, Slovin SF, Siedlecki K, Regan KP, DiPaola RS, Rafi M, Rosen N and Scher HI. Safety and biologic activity of intravenous bcl-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.  Appl Immunohistochem Mol Morphol, 13(1):6-13, 2005.  PMID: 15722787

      Rafi MM, Bai NS, Chi-Tang-Ho, Rosen RT, White E, Perez D and DiPaola RS. A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on bcl-2 phosphorylation.  Anticancer Res, 25(1A):313-8, 2005.  PMID: 15816553

      Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P and DiPaola RS.  A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer.  Prostate, 62(2):115-22, 2005. PMID: 15389797

      Dvorzhinski D, Thalasila A, Thomas PE, Nelson D, Li H, White E and DiPaola RS. A novel proteomic coculture model of prostate cancer cell growth. Proteomics, 4(10):3268-75, 2004.  PMID: 15378687

      Ioffe ML, White E, Nelson DA, Dvorzhinski D and DiPaola RS. Epothilone induced cytotoxicity is dependent on p53 status in prostate cells. Prostate, 61(3):243-7, 2004.  PMID: 15368466

      Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS and Small EJ. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol, 22(18):3705-12, 2004. PMID: 15289492

      Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G and Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 22(11):2122-32, 2004.  PMID: 15169798

      Kumar P, Perrotti M, Weiss R, Todd M, Goodin S Cummings K and DiPaola RS.  Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol, 22(10):1909-15, 2004.  PMID: 15143084

      Yao SL and DiPaola RS.  An evidence-based approach to prostate cancer follow-up. Semin Oncol, 30(3):390-400, 2003.  PMID: 12870141

      Strair RK, Schaar D, Medina D, Todd MB, Aisner J, DiPaola RS, Manago J, Knox B, Jenkinson A, Senzon R, Baker C, Liesel D, Ciardella M, Kuriyan M, Rubin A and Lattime EC.  Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma.  J Clin Oncol, 21(20):3785-91, 2003.  PMID: 1455129

      DiPaola RS, Durivage HJ, Kamen BA.  High time for low-dose prospective clinical trials. Cancer, 98(8)1559-61, 2003.  PMID: 14534869

      Thalasila A, Poplin E, Shih J, Dvorzhinski D, Capanna T, Doyle-Lindrud S, Beers S, Goodin S, Rubin E and DiPaola RS.  A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.  Cancer Chemother Pharmacol, 52(2):119-24, 2003.  PMID: 12768320

      DiPaola RS, Rubin E, Toppmeyer D, Eid J, Butzbach D, Dvorzhinski D, Capanna T, Cairdella  M, Shih JW, Goodin S and Todd MB. Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.  Med Sci Monit, 9(2):PI5-11, 2003.  PMID: 12601301

      DiPaola RS. To arrest or not to G(2)-M cell-cycle arrest: commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin Cancer Res, 8(11):3311-4, 2002.  PMID: 12429616

      Marks LS, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Leaders FE Jr, Pantuck AJ and Tyler VE. PC-SPES: herbal formulation for prostate cancer. Urology, 60(3):369-75, 2002.  PMID: 12350462

      Goodin S, Rao KV and DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer.  Oncologist, 7(4):360-70, 2002.  PMID: 12185298

      Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N and Scher HI. A phase I trial of Bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.  Clin Cancer Res, 8(3):679-83, 2002.  PMID: 11895895

      DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P and Yao SL. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol, 20(7):1874-9, 2002.  PMID: 11919247

      Rafi MM, Vastano BC, Zhu N, Ho CT, Ghai G, Rosen RT, Gallo MA and DiPaola RS.  Novel polyphenol molecule isolated from licorice root (glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. J Agric Food Chem, 50(4):677-84, 2002.  PMID: 11829627

      • Publications 1994 - 2001

        Zhu N, Kikuzaki H, Sheng S, Sang S, Rafi MM, Wang M, Nakatani N, DiPaola RS, Rosen RT and Ho CT. Furanosesquiterpenoids of commiphora myrrh.  J Nat Prod, 64(11):1460-2, 2001.  PMID: 11720534

        DiPaola RS, Patel J and Rafi MM. Targeting apoptosis in prostate cancer.  Hematol Oncol Clin North Am, 15(3):509-24, 2001.  PMID: 11525294

        DiPaola RS, Chenven ES, Shih WJ, Lin Y, Amenta P, Goodin S, Shumate A, Capanna T, Cardiella M, Cummings KB, Aisner J and Todd MB. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate cancer.  Cancer, 92(8):2065-71, 2001.  PMID: 11596021

        Eid JE, Brunner M, Segal L, Cummings KB, Weiss RE, Goodin S, Todd M, Aisner J and DiPaola RS.  Effect of P-30 protein and tamoxifen on TGF-Beta1 and IGF-1 in patients with prostate cancer.  Urol Oncol, 6:243-247, 2001.  PMID: 11423019

        Ankem MK, Hartanto VH, Han KR, Ferlise VJ, Bancila E, Cummings KB and DiPaola RS. Metastatic renal cell carcinoma presenting as an oral tumor. Can J Urol, 8(3):1295-6, 2001.  PMID: 11423019

        Zhu N, Rafi MM, DiPaola RS, Xin J, Chin CK, Badmaev V, Ghai G, Rosen RT and Ho CT.  Bioactive constituents from gum guggul (Commiphora wightii). Phytochemistry, 56(7):723-7, 2001.  PMID: 11314959 

        DiPaola RS, Kumar P, Hait WN, and Weiss RE. State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey.  N J Medicine, 98(2):23-33, 2001.  PMID: 11221439 

        Goodin S and DiPaola RS. Is there science for alternative medicine in prostate cancer? Highlights in Oncology Practice, 18(3):72-76, 2000. 

        Rafi MM, Rosen RT, Vassil A, Ho CT, Zhang H, Ghai G, Lambert G and DiPaola RS. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res, 20(4):2653-8, 2000.  PMID: 10953339

        Cvijic ME, Kita T, Shih W, DiPaola RS and Chin KV.  Extracellular catalytic subunit activity of the cAMP-dependent protein kinase in prostate cancer.  Clin Cancer Res, 6(6):2309-17, 2000.  PMID: 10873081

        DiPaola RS. Approaches to the treatment of patients with hormone-sensitive prostate cancer.  Semin Oncol, 26(5 Suppl 17):24-27, 1999.  PMID: 10604265

        DiPaola RS and Schuchter L.  Neurologic protection by amifostine. Semin Oncol, 26 (2 Suppl 7):82-8, 1999.  PMID: 10348265

        DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, Patel J, Goodin S, Medina M, Medina P, Zamek R, Zhang C, White E, Gupta E and Hait WN. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol, 17(7):2213-8, 1999. PMID: 10561278

        DiPaola RS and Aisner J. Overcoming bcl-2 and p53-mediated resistance in prostate cancer.  Semin Oncol, 26(1 Suppl 2):112-6, 1999.  PMID: 10190792

        Medina PJ, DiPaola RS and Goodin S. Treatment of hormone refractory prostate cancer. J Oncol Pharm Practice, 4(4), 1998.

        DiPaola RS, Hait WN and Gallo M. PC-SPES and prostate cancer, (Letter). N Engl J Med, 340:568, 1999.

        Goodin S and DiPaola RS.  Strategies for using cytoprotective agents to improve outcomes associated with cancer chemotherapy. Disease Management and Clinical Outcomes, 1(5):292-301, 1998.

        DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, Zhu BT, Spaulding H, Goodin S, Toledano MB, Hait WN and Gallo MA.  Clinical and biological activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med, 339(12):785-91, 1998.  PMID: 9738085

        Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV and Fox KR.  First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.  J Clin Oncol, 16(7):2392-400, 1998.  PMID: 9667256

        DiPaola, RS, Rodriquez R, Goodin S, Recio A, Orlick M, Mollman J, Bird S, Belsh J, Schein P, Aisner J and Schuchter L. Amifostine and dose intense paclitaxel in patients with advanced malignancies.  Cancer Ther, 1:11-17, 1998.

        DiPaola RS, Weiss RE, Cummings KB, Kong FM, Jirtle RL, Anscher M, Gallo J, Goodin S, Thompson S, Rasheed Z, Aisner J and Todd MB.  Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen.  Clin Cancer Res, 3(11):1999-2004, 1997.  PMID: 9815590

        DiPaola RS, Goodin S, Ratzell M, Florczyk M, Karp G and Ravikumar TS. Chemotherapy for metastatic melanoma during pregnancy. Gynecol Oncol, 66(3):526-30, 1997. PMID: 9299271

        Salhany KE, Feldman M, Kahn MJ, Peritt D, Schrentzenmair RD, Wilson DM, DiPaola RS, Glick AD, Kant JA, Nowell PC and Kamoun M.  Hepatosplenic gammadelta T-cell lymphoma: ultrastructural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation.  Hum Pathol, 28(6):674-85, 1997.  PMID: 9191001

        DiPaola RS, Kuczynski WI, Onodera K, Ratajczak MZ, Hijiya N, Moore J and Gerwirtz AM. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells.  Cancer Gene Ther, 4(3):176-82, 1997.  PMID: 9171936

        DiPaola RS, Kaufman A and Mikhail MM. Treatment of advanced breast cancer: how much chemotherapy is enough?  Semin Oncol., 23(3):xvii-xxiv, 1996.  PMID: 8658211

        August DA, DiPaola RS, Kearney T and Hait W. A model of comprehensive diagnosis and care for breast cancer patients.  N J Med, 93(5):27-34, 1996. PMID: 8871501

        Luger SM, Ratajczak J, Ratajczak MZ, Kuczynski WI, DiPaola RS, Ngo W, Clevenger CV and Gewirtz AM. A Functional analysis of protooncogene Vav’s role in adult human hematopoiesis. Blood, 87(4):1326-34, 1996.  PMID: 8608221

        DiPaola RS, Orel S and Fowble B.  Ipsilateral breast tumor recurrence after conservative surgery and radiation therapy.  Oncology 8(12):59-68, 1994.  PMID: 7888313


        Invited Lectures / Presentations

        • “The Future of Translational Research; A Cancer Institute Perspective”, University-Industry Demonstration Partnership, Rutgers University, New Brunswick, NJ, April 24, 2012.
        • “The Future of Translational Research with a Focus on Prostate Cancer”, Grand Rounds, Roswell Park Cancer Institute, Buffalo, NY, August 3, 2011.
        • “Translational Research in Prostate Cancer: A Focus on Apoptosis and Autophagy”, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, July 2011.
        • “Prostate Cancer Lecture”, Abbott Oncology Division, Abbott Laboratories, Abbott Park, IL, June 29, 2011.
        • “Autophagy and Apoptosis: Translational Opportunities in Drug Development”, Educational Session, American Association for Cancer Research (AACR) Annual Meeting, Orlando, FL, April 2011.
        • “Overview of Translational Aspects of Drug Development in Prostate Cancer”, General Session, American Society of Clinical Oncology (ASCO) GU Cancer Symposium, Orlando, FL, February 2011.
        • “Targeting Apoptosis and Autophagy in Prostate Cancer”, Prostate Cancer Foundation Scientific Retreat, Washington DC, September 15, 2010
        • “Genitourinary Malignancies”, Morristown Memorial Hospital, Morristown, NJ, June 2010.
        • “Translational Approaches to Autophagy”, National Cancer Institute, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, March 2010.
        • “Symposium on Autophagy”, Co-Chair, National Cancer Institute, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, March 2010.
        • “Translational Approaches and New Paradigms for Prostate Cancer”, NJMS-University Hospital Cancer Center, Newark, NJ, February 2010.
        • “GU Cancers and Future Directions on Cooperative Group Clinical Trials”, Meridian Health’s CME Program Lecture Series, Ocean Medical Center, Brick, NJ, February 2010.
        • “Emerging Challenges in Prostate Cancer”, 3rd Annual Medical College of George Cancer Center and Section of Hematology/Oncology Symposium, Hyatt Regency, Savannah, GA, September 2009.
        • “Genitourinary Malignancies”, Statewide Symposium, Morristown, NJ, June 2009.
        • “Therapeutic Strategies Targeting Apoptosis and Autophagy”, New York Cancer Consortium, New York, NY, May 2009.
        • “Vaccine Therapy in Early Stage Prostate Cancer”, Chemotherapy Foundation Symposium, New York, NY, November 7, 2008.
        • “Translational Approaches to Autophagy”, NCI-AACR-EORTC Molecular Targets Symposium, Geneva, Switzerland, October 2008.
        • “NCI-designated Cancer Center Appropriations”, American Association of Cancer Institutes (AACI) Annual Meeting, Chicago, IL, September 2008.
        • “Translational Research in Prostate Cancer”, Apoptosis and Autophagy Cancer Center Grand Rounds, University of Texas Southwestern Medical Center, Dallas, TX, September 4, 2008.
        • “ECOG State of the Committee Genitourinary Update”, ECOG Offices, Boston, MA, June 28, 2008.
        • “Genitourinary Cancers”, Grand Rounds Symposium, Morristown Memorial Hospital, Morristown, NJ, June 21, 2008.
        • “Highlights for Genitourinary Cancers”, General Session, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, June 3, 2008.
        • “Genitourinary Cancer Update”, Grand Rounds Symposium, Montefiore Medical Center, Albert Einstein University, New York, NY, March 2008.
        • “Clinical Trial Opportunities in Genitourinary Oncology”, American Urologic Society Foundation Clinical Research Symposium, Los Angeles, CA, August 2007.
        • Cooperative Group Phase III Clinical Trials in Genitourinary Cancers”, National Prostate Cancer Symposium, Colorado, February 2007.
        • “Immune Therapy in Prostate Cancer”, National Prostate Cancer Symposium, Colorado, February 2007.
        • “Vaccine Therapy in Prostate Cancer”, Cleveland Clinic Foundation Symposium, October 2006.
        • “Prostate Cancer Resistance and Novel Approaches”, Cambridge Harvard Symposium, Boston, MA, October 2006.
        • “National Directions in Prostate Cancer Clinical Trials”, General Session, American Society of Clinical Oncology (ASCO) Prostate Symposia, San Francisco, CA, February 2006.
        • “Vaccine Therapy in Prostate Cancer”, 16th International Prostate Cancer Symposia, Colorado, January 2006.
        • “Targeted Therapy in Prostate Cancer”, 16th International Prostate Cancer Symposia, Colorado, January 2006.
        • “Prostate Cancer Immunotherapy”, Prostate Cancer Foundation, New York, NY, December 2005.
        • “Targeted Therapy for Prostate Cancer”, American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting, Colorado, 2005.
        • “Grand Rounds: Prostate Cancer”, Mayo Clinic, Jacksonville, FL, November 2005.
        • “Novel Approaches to the Treatment of Androgen Sensitive Prostate Cancer”, International Prostate Cancer Congress, Puerto Rico, July 2005.
        • “Future of Prostate Cancer Therapy”, Albert Einstein University, New York, NY, June 17, 2005.
        • “Tumor Biology Poster Discussion Session”, Chairman, American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, FL, May, 2005.
        • “Pox Vaccine Therapies in Prostate Cancer”, Discussant, American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, FL, May, 2005.
        • “Cooperative Group Clinical Trials”, General Session, American Society of Clinical Oncology (ASCO) Annual Prostate Symposia, Chicago, IL, February 2005.
        • “Targeted Therapies in Prostate Cancer”, 15th International Prostate Cancer Symposia, Vail, CO, February 12, 2005.
        • “Future of Prostate Cancer: Urology/Medical Oncology Symposia on Developing Plans to Increase Cooperative Group Trial Accrual”, Four Seasons Hotel, Chicago, IL, September 18, 2004.
        • “Genitourinary Malignancies: Bench, Bedside, and Cooperative Groups”, Translational GU Symposia, The University of Iowa College of Medicine, Iowa City, IA, June 24-25, 2004.
        • “ASCO Review”, Columbus Community Clinical Oncology Program, Columbus, OH, June 22-23, 2004.
        • “ECOG GU Trials Agenda”, GU Session, American College of Surgeons (ACOSOG), Chicago, IL, July 2004.
        • “Future of Systemic Therapy in Prostate Cancer”, Educational Session, American Society of Clinical Oncology (ASCO) Annual Meeting, New Orleans, LA, June 2004.
        • “Genitourinary Cancer”, NMCR Educational Symposia 10th Annual Meeting, Las Vegas, NV, February 19-20, 2004.
        • “CTEP’s Studies of PROSTVAC and PANVAC”, Therion Biologic, The Crowne Plaza Hotel, October 4, 2003.
        • “ECOG Prostate Debate”, Memorial Sloan-Kettering Cancer Center, Westin Hotel, New York, NY, October 3, 2003.
        • “High Risk Prostate Cancer”, Grand Rounds, Stony Brook University Hospital, Stony Brook, NY, September 25, 2003.
        • “Challenging Cases in Prostate Cancer”, Network for Medical Communication and Research, Chicago, IL, September 19-20, 2003.
        • “Prostate Vaccine Program”, National Cancer Institute (NCI), Marriott Pookshill, Bethesda, MD, August 25, 2003.
        • “ASCO Highlights: Genitourinary Malignancy” Network for Medical Communication and Research, New York, NY, August 9, 2003.
        • “Amonafide Investigators Meeting”, Speaker, Chicago, IL, December 18, 2003.“ASCO Highlights: Overview of Therapy for Genitourinary Cancer”, Network for Medical Communication and Research, Hyatt Regency La Jolla, San Diego, CA, July 26, 2003.
        • “ASCO Highlights: Prostate Cancer Therapy”, Network for Medical Communication and Research, Las Vegas, NV, July, 18, 2003.
        • “Translational Research in Prostate Cancer”, Urology Distinguished Lecture Series, Jefferson Medical Center, Philadelphia, PA, February 2003.
        • “Prostate Cancer”, Montefiore Medical Center Symposia, Albert Einstein University, New York, NY, June 2003.
        • “Prostate Cancer and Bcl-2”, Aventis Advisory Board Meeting, January 2003.
        • "NCI Working Group Research with PC-SPES”, National Cancer Institute (NCI), Bethesda, MD, August 12, 2002.
        • “NCI PSA Vaccine Working Group”, National Cancer Institute (NCI), Bethesda, MD, July 19, 2002.
        • “Prostate Symposia”, National Prostate Symposia (NMCR), Inverness, CO, July 26, 2002.
        • “Cytotoxic Therapy in Prostate Cancer”, IPCME, St. Petersburg, FL, July 12, 2002.
        • “ASCO Highlights: GU Oncology”, Network for Medical Communication and Research, San Diego, CA, June 30, 2002.
        • “Prostate Cancer”, National Prostate Symposia (NMCR), New York, NY, June 14, 2002.